secwatch.observer — SEC 8-K summary
======================================

Issuer:     ELITE PHARMACEUTICALS INC /NV/ (ELTP)
CIK:        0001053369
Form:       8-K
Filed at:   2026-08-04T11:05:28+00:00
Accession:  0001493152-26-035922
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Elite Pharmaceuticals launches generic Requip XL; addresses $10M U.S. market
----------------------------------------------------------------------------

- Launched generic Ropinirole Extended-Release Tablets (2, 4, 6, 8, 12 mg) for Parkinson's disease.
- Product marketed under Elite Laboratories label; branded Requip XL and equivalents had $10M U.S. sales (IQVIA, 12 months ending June 2026).
- Expands Elite's niche generic portfolio; company operates cGMP/DEA-registered facility in Northvale, NJ.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1053369/000149315226035922/0001493152-26-035922-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1053369/000149315226035922/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-035922

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer